Maxwell Biotech Venture Fund (MBVF), a Russian venture fund company that invests in the life sciences sector, has opened an office in Boston at 420 Boylston St. MBVF is a $100 million fund earmarked for investments in medical innovations and biotechnology. Begun as a public-private partnership between Russian Venture Company (RVC) and private investors, it is managed by Maxwell Asset Management. Transactions undertaken by MBVF have included investments and licensing collaborations with US companies Sequella, AtheroNova, Bionevia and Dental Photonics. MBVF representatives will be working with colleagues from RVC USA Inc.